← Russell 3000 cross-section

LMAT LEMAITRE VASCULAR INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1.8bn
Revenue TTM
$262m
Net income TTM
$66m
Free cash flow
$74m
Composite score
72.6
Sector rank
#1696

Valuation

P / E
27.7
EV / EBITDA
16.4
EV / sales
5.5
FCF yield
4.06%
Earnings yield vs 10-yr
-1.12pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
25.0%
EBITDA margin
33.5%
ROE
15.6%
ROIC
175.3%
Revenue growth
11.8%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In Q2 2026, biologics represented 55% of our worldwide sales. Our business opportunities include the following: • growing our direct sales force in North America, Europe, and APAC, including replacing distributors with our direct sales personnel; • increasing the average selling prices of our devices; • introducing our products into new territories upon receipt of regulatory approvals or registrations; • acquiring complementary products and transitioning distributor sales to LeMaitre; • updating existing products and introducing new products through research and development; and • consolidating product manufacturing into our Burlington, Massachusetts facilities. …LEMAITRE VASCULAR INC, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →